Why the Probiotec (ASX:PBP) share price is surging 7% today

The company's latest trading update has boosted investor confidence. We take a closer look…

| More on:
green arrow representing a rise in the share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Probiotec Limited (ASX: PBP) share price is on the move during late afternoon trade. This comes after the pharmaceutical products company provided investors with a trading update and earnings guidance for FY21.

At the time of writing, Probiotec shares are up 7.18% to $2.09.

How is Probiotec performing in FY21? 

Investors are snapping up Probiotec shares following the company's trading update and strong earnings outlook.

According to its release, Probiotec announced it is continuing to deliver on its strategy, increasing value for shareholders. Both existing and new customers have inquired about the company's onshore manufacturing capability.

The company stated that its pharmaceutical product categories affected by COVID-19 are beginning to recover. It is anticipated that this will progressively improve throughout the first-half of FY22, with normal levels returning in H2 FY22.

Although, the current lockdown in Victoria is expected to have a slight impact on the overall group's earnings for FY21.

Pleasingly, Probiotec's recent acquisition of Multipack-LJM in January this year has performed in line with expectations for the 6 months. The business' earnings are weighted more towards the second-half end of the year (July to December). With that in mind, the company is focused on using Multipack-LJM's toolkit to attract more customers and drive revenue growth.

Looking ahead, Probiotec is forecasting revenue to be in the range of $118 million to $122 million. This is a minimum increase of 10% on FY20's result of $107 million.

Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) is projected to come between $21 million and $22 million. When compared against the prior corresponding period ($16.9 million in FY20), this is around a 25% jump.

Underlying earnings per share (EPS) is predicted to drop from FY20's result (11.1 cents per share). This metric is assumed to fall somewhere between 10 cents and 11 cents per share.

Probiotec share price snapshot

In November, Probiotec shares raced higher following notice of its planned acquisition of contract packing specialist, Multipack-LJM. The company's share price reached an all-time high of $2.50 when the takeover was completed in January.

Since then, Probiotec shares have been on a downhill trend, posting a loss of 12% on year-to-date share price performance.

Based on today's price, Probiotec has a market capitalisation of roughly $163 million, with 78 million shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Probiotec Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

The market didn't like what this stock had to say this morning...

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

ResMed shares are up 42% in a year. This shows why they could still be great value

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 buy-rated ASX 200 healthcare shares to bring your portfolio to life in 2025

Bell Potter is expecting healthy returns from these stocks this year.

Read more »

two young boys dressed in business attire and wearing spectacles sit side by side and watch closely an old fashioned television box receiver with built in wire ariels.
Healthcare Shares

Here are the important dates impacting CSL shares this year

Here's when CSL will announce its dividends and release its financial reports to the market.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Healthcare Shares

Why is the Mesoblast share price crashing 9% today?

What is weighing on this high-flying stock on Tuesday? Let's find out.

Read more »

Healthcare Shares

Guess which ASX 200 share is up 7% after smashing FY24 guidance

This growing company has outperformed expectations in FY 2024 with another impressive 12 months.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Sigma shares race to another record high. What's next?

What's next for the new-and-improved healthcare giant?

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Up 120% in a year, ASX 200 healthcare stock dips on US acquisition

The ASX 200 healthcare company announced a strategic new US acquisition.

Read more »